Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 20Neoplasm Metastasis 3Sleep Initiation and Maintenance Disorders 1Prostatic Diseases 1Prostate Cancer Metastatic Disease 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Diseases, Male 1Fatigue 1Depression 1Adenocarcinoma 1

Interventions

famitinib 1enzalutamide 1apalutamide 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Drug Therapy 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoadjuvant Therapy × apalutamide × Clear all
NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
900 enrolled
Genitourinary

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡